CASTLE BIOSCIENCES INC

CSTL

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RTW Investments Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$11.9M

1 fund

Feb 17, 2026

$82.3M

1 fund

+593% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 2,115,237Value: $82.3M

# Signal Note: RTW Investments Initiates $82.3M Position in CSTL RTW's substantial entry into Castle Biosciences signals confidence in the company's dermatologic diagnostics portfolio, particularly its melanoma risk stratification tests (DecisionDx-Melanoma) and broader oncology expansion. The timing suggests conviction ahead of potential upcoming data readouts or commercial inflection points, though near-term catalysts (specific trial readouts, reimbursement decisions, or revenue acceleration) should be monitored to validate the thesis.

Eventide Asset ManagementNEW

More CSTL Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IVEVF2 funds QURE2 funds SYK2 funds WVE2 funds CYTK2 funds IRON2 funds CGON2 funds BBNX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide Initiates $11.9M CSTL Position** Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC diagnostic platforms address high-margin, recurring-revenue opportunities in melanoma and squamous cell carcinoma risk stratification, with reimbursement stability and expanding clinical adoption as primary value drivers. Eventide's entry—consistent with its values-based biotech focus on differentiated diagnostics—suggests conviction in execution visibility, likely tied to upcoming 2024-2025 revenue inflection from Medicare coverage expansion and international rollout rather than binary clinical catalysts.